Products
Sonavibart Biosimilar Monoclonal Antibody (Influenza A Hemagglutinin) for Research
Cat No.: GMP-Bios-INN-1393
Anti-Influenza A HA therapeutic antibody (Pre-made Sonavibart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Sonavibart (development code MEDI8852) is a monoclonal antibody targeting influenza A virus hemagglutinin HA. It is developed by Humabs BioMed and AstraZeneca for Influenza A virus infections in Phase II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1393-1mg | 1mg | 3090 |
| GMP-Bios-INN-1393-10mg | 10mg | |
| GMP-Bios-INN-1393-100mg | 100mg | |
| GMP-Bios-INN-1393-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Sonavibart biosimilar, Whole mAb: Anti-Influenza A HA therapeutic antibody |
| INN Name | Sonavibart |
| Target | Influenza A HA |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | 5jw3:HL/5jw4:MN:OP:QR:ST:UV:WX/5jw5:HL:AB |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2024 |
| Year Recommended | na |
| Companies | Humabs BioMed;AstraZeneca |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Influenza A virus infections |
| Production | na |
| Development Tech | na |
